Substrate
science

Study Examines How Anti-PD-1 Antibodies Affect Immune Cell Signaling

A new study published in Science Immunology reports that anti-PD-1 antibodies trap PD-1 proteins at nanoscale immune contacts and trigger inhibitory checkpoint signaling. The findings identify potential targets for improving immunotherapy design.

SC
1 source·May 23, 5:32 PM·1m read
Study Examines How Anti-PD-1 Antibodies Affect Immune Cell Signalingprweb.com
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

Researchers observed that the antibodies hold PD-1 at specific nanoscale sites where immune cells meet. This positioning leads to increased inhibitory checkpoint signaling. The work describes mechanisms that may influence how current immunotherapies function at the cellular level.

The study focused on events at immune synapses, the contact points between immune cells. Measurements showed that trapped PD-1 remained at these sites longer than in untreated conditions. Data indicated that prolonged presence of PD-1 at the contact area correlated with stronger inhibitory signals.

The authors noted that these observations could guide adjustments in antibody structure or dosing. No named individuals or institutions were identified in the report beyond the journal in which the study appeared.

Transparency

Confidence75%

Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.

Story details

Related Stories

Bundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italynypost.com
science23 hrs ago

Bundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italy

Four nurses and one laboratory worker have recovered from Ebola caused by the Bundibugyo strain in the Democratic Republic of Congo. Suspected cases linked to travel from affected countries are under investigation in Brazil and Italy.

Cnn
AllAfrica
dimsumdaily.hk
3 sources
Phase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic CancerNew Scientist
science13 hrs ago

Phase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer

A 500-person study found the once-daily pill halted or reversed tumor progression in nearly one-third of patients versus 10 percent on chemotherapy. Median survival rose from less than seven months to roughly 13 months.

Cbc
New Scientist
2 sources
science1 day ago

Wildfire Insured Losses Hit $54 Billion in 2025, Highest on Record

A new analysis published Sunday found that insured losses from wildfires worldwide hit at least $54 billion in 2025, the highest level on record. The Los Angeles fires and blazes in South Korea and Spain drove the total.

The New York Times
1 source